BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Martek Biosciences (MATK) Announces Proposed Offering Of 1,500,000 Shares Of Common Stock


10/19/2005 5:12:20 PM

COLUMBIA, Md., Jan. 13 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation , today announced that it plans to conduct an underwritten offering of 1,500,000 shares of its common stock under an existing shelf registration statement. In connection with the offering, Martek expects to grant the underwriters an option to purchase up to 225,000 additional shares to cover over-allotments.

Citigroup will act as sole bookrunning manager of the offering. Adams Harkness, Inc. will act as co-lead manager and Needham & Company, Inc., First Albany Capital and D.A. Davidson & Co. will act as co-managers.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A preliminary prospectus supplement relating to these securities has been filed with the Securities and Exchange Commission. This offering of the shares of common stock may be made only by means of the preliminary prospectus supplement and related prospectus, copies of which will be available from Citigroup Global Markets Inc., 388 Greenwich Street, New York, New York 10013.

Martek Biosciences Corporation develops, manufactures and sells products from microalgae. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) new, powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection.

CONTACT: Pete Buzy, Chief Financial Officer, of Martek Biosciences Corporation, +1-410-740-0081.

Martek Biosciences Corporation

CONTACT: Pete Buzy, Chief Financial Officer, of Martek BiosciencesCorporation, +1-410-740-0081



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES